Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
11 2021
Historique:
received: 02 04 2021
revised: 02 08 2021
accepted: 18 08 2021
pubmed: 10 9 2021
medline: 5 2 2022
entrez: 9 9 2021
Statut: ppublish

Résumé

Patients with oropharyngeal squamous cell carcinoma (OPSCC) display a significant risk to develop a metachronous second primary neoplasia (MSPN). HPV and non-HPV-related OPSCC are 2 distinct entities with biological, clinical and prognostic differences. The aims of our study were to analyze the impact of tumor HPV status and other relevant clinical factors, such as tobacco and/or alcohol (T/A) consumption, on the risk and distribution of MSPN in OPSCC patients and to assess the impact of MSPN on patient survival. All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. P16 immunohistochemical expression was used as a surrogate maker of tumor HPV status. The impact of tumor p16 status on the risk of MSPN was assessed in uni- and multivariate analyses. Overall survival (OS) was determined by Kaplan-Meier analysis. Among the 1291 patients included in this study, 138 (10.7%) displayed a MSPN which was preferentially located in the head and neck area (H&N), lung and esophagus. Multivariate analyses showed that p16- tumor status (p = 0.003), T/A consumption (p = 0.005) and soft palate tumor site (p = 0.009) were significantly associated with a higher risk of MSPN. We found no impact of p16 tumor status on the median time between index OPSCC diagnosis and MSPN development, but a higher proportion of MSPN arising outside the H&N, lung and esophagus was found in p16 + than in p16- patients. MSPN development had an unfavorable impact (p = 0.04) on OS only in the p16 + patient group. P16 tumor status and T/A consumption were the main predictive factors of MSPN in OPSCC patients. This study provides crucial results with a view to tailoring global management and follow-up of OPSCC patients.

Identifiants

pubmed: 34500315
pii: S1368-8375(21)00609-6
doi: 10.1016/j.oraloncology.2021.105503
pii:
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p16 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

105503

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Florent Milliet (F)

Department of Otorhinolaryngology, University Hospital of Nice, France.

Alexandre Bozec (A)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Renaud Schiappa (R)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Julien Viotti (J)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Anouchka Modesto (A)

Department of Radiotherapy, Cancer University Institute of Toulouse, Toulouse, France.

Olivier Dassonville (O)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Gilles Poissonnet (G)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Bruno Guelfucci (B)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Alain Bizeau (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Sebastien Vergez (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Agnes Dupret-Bories (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Renaud Garrel (R)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Montpellier, Montpellier, France.

Nicolas Fakhry (N)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Laure Santini (L)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Benjamin Lallemant (B)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Guillaume Chambon (G)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Anne Sudaka (A)

Department of Pathology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Frederic Peyrade (F)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Esma Saada-Bouzid (E)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Karen Benezery (K)

Department of Radiotherapy, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Florence Jourdan-Soulier (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Françoise Chapel (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Anne Sophie Ramay (A)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Pascal Roger (P)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Thibault Galissier (T)

Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France.

Valérie Coste (V)

Department of Pathology, University Hospital of Montpellier, Montpellier, France.

Aicha Ben Lakdar (A)

Department of Pathology, Gustave Roussy Institute, Villejuif, France.

Joanne Guerlain (J)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Stephane Temam (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Haitham Mirghani (H)

Otolaryngology and Head and Neck Surgery Department, European Hospital Georges Pompidou, APHP, Paris, France.

Phillipe Gorphe (P)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Emmanuel Chamorey (E)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Dorian Culié (D)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France. Electronic address: dorian.culie@nice.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH